Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans (Q73052591)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10511062 AND SRC:MED&resulttype=core&format=json

31 October 2019

title

Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10511062 AND SRC:MED&resulttype=core&format=json

31 October 2019

1 reference

1 reference

T Furuta

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10511062 AND SRC:MED&resulttype=core&format=json

31 October 2019

K Ohashi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10511062 AND SRC:MED&resulttype=core&format=json

31 October 2019

K Kobayashi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10511062 AND SRC:MED&resulttype=core&format=json

31 October 2019

I Iida

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10511062 AND SRC:MED&resulttype=core&format=json

31 October 2019

H Yoshida

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10511062 AND SRC:MED&resulttype=core&format=json

31 October 2019

N Shirai

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10511062 AND SRC:MED&resulttype=core&format=json

31 October 2019

M Takashima

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10511062 AND SRC:MED&resulttype=core&format=json

31 October 2019

K Kosuge

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10511062 AND SRC:MED&resulttype=core&format=json

31 October 2019

H Hanai

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10511062 AND SRC:MED&resulttype=core&format=json

31 October 2019

K Chiba

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10511062 AND SRC:MED&resulttype=core&format=json

31 October 2019

T Ishizaki

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10511062 AND SRC:MED&resulttype=core&format=json

31 October 2019

E Kaneko

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10511062 AND SRC:MED&resulttype=core&format=json

31 October 2019

publication date

1 September 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10511062 AND SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

31 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10511062 AND SRC:MED&resulttype=core&format=json

31 October 2019

volume

66

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10511062 AND SRC:MED&resulttype=core&format=json

31 October 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10511062 AND SRC:MED&resulttype=core&format=json

31 October 2019

page(s)

265-274

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10511062 AND SRC:MED&resulttype=core&format=json

Helicobacter pylori infection

31 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(99)70034-2

PROSPECTIVE DOUBLE-BLIND TRIAL OF DUODENAL ULCER RELAPSE AFTER ERADICATION OF CAMPYLOBACTER PYLORI

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(99)70034-2

Management strategies for Helicobacter pylori-seropositive patients with dyspepsia: clinical and economic consequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(99)70034-2

The Treatment ofHelicobacter pyloriInfection in the Management of Peptic Ulcer Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(99)70034-2

Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(99)70034-2

Proposed mechanism for metronidazole resistance in Helicobacter pylori

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(99)70034-2

The pharmacology of the gastric acid pump: the H ,K ATPase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(99)70034-2

Omeprazole in the treatment of peptic ulcers resistant to H2-receptor antagonists.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(99)70034-2

Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(99)70034-2

Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(99)70034-2

Interphenotype differences in disposition and effect on gastrin levels of omeprazole—suitability of omeprazole as a probe for CYP2C19

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(99)70034-2

Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(99)70034-2

Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(99)70034-2

Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(99)70034-2

CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(99)70034-2

Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(99)70034-2

Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(99)70034-2

Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(99)70034-2

Simultaneous determination of omeprazole and its metabolites in plasma and urine by reversed-phase high-performance liquid chromatography with an alkaline-resistant polymer-coated C18 column

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(99)70034-2

Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(99)70034-2

Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(99)70034-2

Cancer after exposure to metronidazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(99)70034-2

Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(99)70034-2

Pharmacokinetic drug interactions of macrolides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(99)70034-2

Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(99)70034-2

Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(99)70034-2

Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(99)70034-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Campylobacter pylori and peptic ulcer disease

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(99)70034-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Oxygen concentration influences proton pump inhibitor activity against Helicobacter pylori in vitro

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(99)70034-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0009-9236(99)70034-2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10511062 AND SRC:MED&resulttype=core&format=json

31 October 2019

1 reference